BRCA1 and BRCA2 are tumor suppressor genes, and defective tumors with loss of the copy of either gene are shown to be intrinsically sensitive to PARP inhibitors in both pre-clinical and clinical models (20, 21). This evidence concerns the gene PARP1 and neoplasm.